Hui Wang

Hui Wang


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2019 in Materials Research Express
Verified
Journal Article
Closed access
PDF file
XRXiangxiang Ren
Xiangxiang Ren
ZXZhangpeng Xu
Zhangpeng Xu
LWLinbo Wang
Linbo Wang
KMKai Meng
Kai Meng
HWHui Wang
Hui Wang
Huijing ZhaoHuijing Zhao
Huijing Zhao

5 April 2010 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
DGDongsheng Guo
Dongsheng Guo
BWBaofeng Wang
Baofeng Wang
FHFuxin Han
Fuxin Han
HWHui Wang
Hui Wang
(2010). RNA interference therapy for glioblastoma. Expert Opinion on Biological Therapy: Vol. 10, No. 6, pp. 927-936. doi: 10.1517/14712598.2010.481667

5 May 2021 in Journal of Molecular Histology
Verified
Journal Article
Closed access
PDF file
CYChen Yang
Chen Yang
PYPengyi Yu
Pengyi Yu
FYFangfang Yang
Fangfang Yang
QHQian He
Qian He
BJBo Jiang
Bo Jiang
LZLei Zhang
Lei Zhang

19 November 2020 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
PDF file
HWHui Wang
Hui Wang
TPTianjie Pu
Tianjie Pu
BWBing Wei
Bing Wei
YFYingying Fan
Yingying Fan
LYLibo Yang
Libo Yang
HBHong Bu
Hong Bu
Aims The aim of this study was to analyse the clinicopathological features and prognosis of human epidermal growth factor receptor-2 (HER2)-positive metaplastic squamous cell carcinoma (MSCC). Methods Fifty-eight patients with MSCC of the breast who were classified into 45 triple-negative and 13 HER2-positive subgroups diagnosed at the West China Hospital, Sichuan University, from 2004 to 2018, were enrolled. Clinicopathological features were collected and compared between HER2-positive MSCC, triple-negative MSCC, HER2-positive invasive breast carcinoma of no special type (NST) and triple-negative NST groups. In the prognostic survival analysis, HER2-positive MSCCs was compared with triple-negative MSCCs, HER2-positive NSTs and triple-negative NSTs. Results Compared with triple-negative MSCCs, more patients with Ki-67 low expression were in HER2-positive MSCCs (p<0.05). More patients with HER2-positive MSCC than patients with HER2-positive NST were postmenopausal (p<0.05). Compared among HER2-positive MSCCs, triple-negative MSCCs and triple-negative NSTs, patients of HER2-positive MSCCs with high Ki-67 expression were the least, and HER2-positive MSCCs had more strongly associated with postmenopausal disease status (p<0.05). In survival analyses, HER2-positive MSCCs had a high risk of recurrence and poor prognosis (p<0.05). Lymph node status was significantly associated with the disease-free survival of patients with HER2-positive MSCC. Conclusion In conclusion, our study indicates that HER2-positive MSCC is an aggressive disease with unique clinicopathological characteristics. Both HER2-positive status and an SCC component are critical factors for poor prognosis. HER2-positive MSCC and triple-negative MSCC are distinct subgroups. Corresponding targeted therapy recommendations should be made for this HER2-positive MSCC group.

13 August 2020 in Journal of International Medical Research
Verified
Journal Article
Open access
PDF file
WZWei Zhao
Wei Zhao
TCTong-Bing Chen
Tong-Bing Chen
HWHui Wang
Hui Wang
Objective: The aim of the present study was to assess the expression of the Ikaros transcription factor (IKZF1) in lung adenocarcinoma and investigate whether expression levels of Ikaros are correlated with lung adenocarcinoma progression. Methods: We conducted a retrospective study of 325 cases of resected stage I pulmonary adenocarcinoma, in which histological subtyping was performed according to the 2015 World Health Organization classification. We performed immunohistochemical examinations to assess expression of Ikaros in pulmonary adenocarcinomas and evaluated the correlation between Ikaros expression and cancer progression. Results: Immunohistochemical staining was heterogeneous, with the majority of well-differentiated and moderately differentiated lung adenocarcinomas being weakly positive and the majority of the poorly differentiated lung adenocarcinomas exhibiting strong positive staining. Higher expression of Ikaros was associated with tumor recurrence or metastasis. Conclusions: Ikaros is heterogeneously expressed in different subtypes of lung adenocarcinoma; higher expression of Ikaros was found to be associated with cancer progression.

31 January 2023 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
TLTing Lei
Ting Lei
YSYongqiang Shi
Yongqiang Shi
WDWenyue Da
Wenyue Da
CXCunyan Xia
Cunyan Xia
HWHui Wang
Hui Wang